Astellas Pharma and Pfizer said FDA has approved a supplemental New Drug Application for Xtandi (enzalutamide), following FDA Priority Review designation, based on results from the phase III PROSPER trial.
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
